Rathbones Group PLC Sells 71,276 Shares of Edwards Lifesciences Corporation $EW

Rathbones Group PLC trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 81.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 16,695 shares of the medical research company’s stock after selling 71,276 shares during the quarter. Rathbones Group PLC’s holdings in Edwards Lifesciences were worth $1,423,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in EW. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the third quarter valued at about $25,000. True Wealth Design LLC raised its holdings in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares during the last quarter. Dorato Capital Management bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $29,000. Finally, Rakuten Securities Inc. raised its holdings in shares of Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on EW. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Evercore restated an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Finally, Wells Fargo & Company lifted their price target on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $95.96.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 24,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the transaction, the vice president owned 33,934 shares of the company’s stock, valued at $2,747,975.32. The trade was a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 74,077 shares of company stock worth $6,165,444. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Down 0.5%

EW opened at $80.80 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The company has a market cap of $46.59 billion, a price-to-earnings ratio of 44.16, a price-to-earnings-growth ratio of 2.11 and a beta of 0.95. The firm has a 50 day simple moving average of $81.53 and a 200 day simple moving average of $81.93. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.